# Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Pati

Source: https://onco.cc/trials/nct04929041/  
OnCo record `nct04929041` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of ipilimumab and nivolumab in lung cancer, run by National Cancer Institute (NCI), active but no longer recruiting.

## Summary

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative is a phase 2/3, randomised interventional study registered as NCT04929041 by National Cancer Institute (NCI), with a registry enrolment figure of 427 participants, started 2022-10-07 and due to reach its primary completion in 2030-12-12. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Echocardiography Test; Ipilimumab; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography; Quality-of-Life Assessment; Radiation Therapy. Conditions listed: Lung Adenocarcinoma; Lung Adenosquamous Carcinoma; Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8. Primary outcome: Progression-free survival (PFS) (Phase II); Overall survival (OS) (Phase III). Lung eligibility wording from the registry: "* Histologic or cytologic diagnosis of stage IV NSCLC using version American Joint Committee on Cancer (AJCC) 8th edition (includes M1a, M1b, and M1c stage disease)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04929041
- Phase: 2/3
- Setting: A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 427

## Sources

- ClinicalTrials.gov NCT04929041: https://clinicaltrials.gov/study/NCT04929041

## Connected records

- cancers: [Adenocarcinoma of the lung](https://onco.cc/cancers/lung-adenocarcinoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04929041.json